OncoMatch/Clinical Trials/NCT06462183
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Is NCT06462183 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies RGT-61159 for adenoid cystic carcinoma.
Treatment: RGT-61159 — Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Biomarker criteria
Allowed: RAS wild-type
if RAS wild-type, an anti-EGFR therapy
Prior therapy
Must have received: fluoropyrimidine-based chemotherapy
must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies
Must have received: oxaliplatin-based chemotherapy
must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies
Must have received: irinotecan-based chemotherapy
must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies
Must have received: anti-VEGF agent
must have been previously treated with, or are not considered candidates for, available therapies including ... anti-VEGF agents
Must have received: anti-EGFR therapy
if RAS wild-type, an anti-EGFR therapy
Cannot have received: MYB inhibitor
Prior treatment with a MYB inhibitor
Lab requirements
Blood counts
adequate hematologic status
Kidney function
renal function
Liver function
liver function and prothrombin time (PT) or INR ≤ 1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
Adequate hematologic status, organ function, renal function, liver function and prothrombin time (PT) or INR ≤ 1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- Washington University School of Medicine · St Louis, Missouri
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, New York
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06462183 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MYB inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify